Atanasio Pandiella

Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer

E. Dı́az-Rodrı́guez, A. Pandiella, Elena Díaz-Rodríguez, 2018, International journal of oncology.

The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype

E. Colado, J. Montero, A. Pandiella, 2008, Haematologica.

Mitogen-activated protein kinase routes as targets in the action of diaza-anthracene compounds with a potent growth-inhibitory effect on cancer cells.

Javier León, J. Montero, A. Pandiella, 2002, Molecular cancer therapeutics.

Personalized therapies in the cancer "omics" era

A. Pandiella, A. Ocaña, Alberto Ocaña, 2010, Molecular Cancer.

Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy

Rajesh Chopra, Bruno Paiva, J. Miguel, 2014, Molecular Cancer Therapeutics.

Preclinical development of molecular-targeted agents for cancer

Lillian L. Siu, I. Tannock, A. Pandiella, 2011, Nature Reviews Clinical Oncology.

Transforming Growth Factor (cid:2) Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab (cid:1) †

Carlos L. Arteaga, Christine H. Chung, Joel Parker, 2008 .

HER3 overexpression and survival in solid tumors: a meta-analysis.

A. Pandiella, F. Vera-Badillo, A. Ocaña, 2013, Journal of the National Cancer Institute.

Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors

J. Montero, A. Pandiella, S. Seoane, 2011, Clinical Cancer Research.